4D pharma to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

4D pharma plc (NASDAQ: LBPS), a leader in Live Biotherapeutic products, announced that CEO Duncan Peyton will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing on the company's website for 90 days. 4D pharma specializes in the development of drugs derived from the microbiome, utilizing its proprietary MicroRx® platform. The company has five clinical programs, including studies in solid tumors and asthma, and is poised to initiate Phase I trials on additional candidates.

LEEDS, UK,--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.

A replay webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com for 90 days following the presentation.

About 4D pharma

4d pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4d pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson’s disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer. The Company has a research collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005720/en/

4D

Investor Relations ir@4dpharmaplc.com

Singer Capital Markets - Nominated Adviser and Joint Broker

Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496 3000

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker

Dominic Wilson +44 (0)20 7332 2500

Stern Investor Relations

Julie Seidel +1-212-362-1200

julie.seidel@sternir.com

Image Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

neil@ibcomms.agency / michelle@ibcomms.agency

Source: 4D pharma

FAQ

What is the significance of 4D pharma's participation in the H.C. Wainwright Global Investment Conference?

4D pharma's CEO, Duncan Peyton, will present the company's advancements in Live Biotherapeutics at the H.C. Wainwright Global Investment Conference on May 24, 2022, highlighting its innovative approaches and clinical programs.

When will 4D pharma's presentation at the conference be available for viewing?

The presentation by CEO Duncan Peyton will be available for on-demand viewing starting May 24, 2022, at 7:00 a.m. ET.

What clinical programs does 4D pharma have related to Live Biotherapeutics?

4D pharma currently has five clinical programs, including studies for solid tumors, asthma, irritable bowel syndrome, and a new study expected in Parkinson’s disease in 2022.

Where can I find the replay of 4D pharma's presentation?

A replay of the presentation will be available in the 'Events' section of 4D pharma's website for 90 days post-presentation.

What are Live Biotherapeutics and how does 4D pharma utilize them?

Live Biotherapeutics are a novel class of drugs defined by the FDA that contain live organisms for treating diseases. 4D pharma develops these using its proprietary MicroRx® platform.